Intracranial gadolinium deposition after contrast-enhanced MR imaging

Radiology

Volumn 275, Issue 3, 2015, Pages 772-782

  McDonald, Robert J ^a   McDonald, Jennifer S ^a   Kallmes, David F ^a   Jentoft, Mark E ^a   Murray, David L ^a   Thielen, Kent R ^a   Williamson, Eric E ^a   Eckel, Laurence J ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADODIAMIDE; CONTRAST MEDIUM; GADOLINIUM;

ADULT; AGED; ARTICLE; AUTOPSY; CAPILLARY ENDOTHELIUM; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DENTATE NUCLEUS; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BRAIN LEVEL; DRUG EXPOSURE; GLOBUS PALLIDUS; HUMAN; HUMAN TISSUE; INTERSTITIUM; KIDNEY FUNCTION; MASS SPECTROMETRY; MIDDLE AGED; MULTIPLE DRUG DOSE; NERVOUS TISSUE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PONS; PRIORITY JOURNAL; THALAMUS; VERY ELDERLY; YOUNG ADULT; BRAIN; METABOLISM; PROCEDURES; RETROSPECTIVE STUDY; TISSUE DISTRIBUTION;

ADULT; AGED; AGED, 80 AND OVER; BRAIN; CONTRAST MEDIA; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; RETROSPECTIVE STUDIES; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 84930850951     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.15150025     Document Type: Article

References (33)

1. Hao D, Ai T, Goerner F, Hu X, Runge VM, Tweedle M. MRI contrast agents: basic chemistry and safety. J Magn Reson Imaging 2012;36(5):1060-1071.
2. Edelman RR, Warach S. Magnetic resonance imaging (2). N Engl J Med 1993;328(11):785-791.
3. Edelman RR, Warach S. Magnetic resonance imaging (1). N Engl J Med 1993;328(10):708-716.
4. Zhou Z, Lu ZR. Gadolinium-based contrast agents for magnetic resonance cancer imaging. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2013;5(1):1-18.
5. Caravan P, Ellison JJ, McMurry TJ, Lauffer RB. Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev 1999;99(9):2293-2352.
6. Aime S, Caravan P. Biodistribution of gadolinium-based contrast agents, including gadolinium deposition. J Magn Reson Imaging 2009;30(6):1259-1267.
7. Cacheris WP, Quay SC, Rocklage SM. The relationship between thermodynamics and the toxicity of gadolinium complexes. Magn Reson Imaging 1990;8(4):467-481.
8. Oksendal AN, Hals PA. Biodistribution and toxicity of MR imaging contrast media. J Magn Reson Imaging 1993;3(1):157-165.
9. Grobner T. Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006;21(4):1104-1108.
10. High WA, Ayers RA, Chandler J, Zito G, Cowper SE. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007;56(1):21-26.
11. Amet S, Launay-Vacher V, Clément O, et al. Incidence of nephrogenic systemic fibrosis in patients undergoing dialysis after contrast-enhanced magnetic resonance imaging with gadolinium-based contrast agents: the Prospective Fibrose Nephrogénique Systémique study. Invest Radiol 2014;49(2):109-115.
12. American College of Radiology Committee on Drugs and Contrast Media. ACR manual on contrast media. 9th ed. Reston, Va: American College of Radiology, 2013.
13. Moreau JF, Droz D, Sabto J, et al. Osmotic nephrosis induced by water-soluble triiodinated contrast media in man: a retrospective study of 47 cases. Radiology 1975;115(2):329-336.
14. Errante Y, Cirimele V, Mallio CA, Di Lazzaro V, Zobel BB, Quattrocchi CC. Progressive increase of T1 signal intensity of the dentate nucleus on unenhanced magnetic resonance images is associated with cumulative doses of intravenously administered gadodiamide in patients with normal renal function, suggesting dechelation. Invest Radiol 2014;49(10):685-690.
15. Kanda T, Ishii K, Kawaguchi H, Kitajima K, Takenaka D. High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology 2014;270(3):834-841.
16. Roccatagliata L, Vuolo L, Bonzano L, Pichiecchio A, Mancardi GL. Multiple sclerosis: hyperintense dentate nucleus on unenhanced T1-weighted MR images is associated with the secondary progressive subtype. Radiology 2009;251(2):503-510.
17. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130(6):461-470.
18. Erickson BJ, Ryan WJ, Gehring DG. Functional requirements of a desktop clinical image display application. J Digit Imaging 2001;14(2 Suppl 1):149-152.
19. Rasband WS. ImageJ. Bethesda, Md: U.S. National Institutes of Health, 1997-2014.
20. R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2012.
21. Kaplan GD, Aisen AM, Aravapalli SR. Preliminary clinical trial of gadodiamide injection: a new nonionic gadolinium contrast agent for MR imaging. J Magn Reson Imaging 1991;1(1):57-62.
22. VanWagoner M, O'Toole M, Worah D, Leese PT, Quay SC. A phase I clinical trial with gadodiamide injection, a nonionic magnetic resonance imaging enhancement agent. Invest Radiol 1991;26(11):980-986.
23. Harpur ES, Worah D, Hals PA, Holtz E, Furuhama K, Nomura H. Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent. Invest Radiol 1993;28(Suppl 1):S28-S43.
24. Van Wagoner M, Worah D. Gadodiamide injection: first human experience with the nonionic magnetic resonance imaging enhancement agent. Invest Radiol 1993;28(Suppl 1):S44-S48.
25. Brasch RC, Weinmann HJ, Wesbey GE. Contrast-enhanced NMR imaging: animal studies using gadolinium-DTPA complex. AJR Am J Roentgenol 1984;142(3):625-630.
26. Weinmann HJ, Laniado M, Mützel W. Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. Physiol Chem Phys Med NMR 1984;16(2):167-172.
27. White GW, Gibby WA, Tweedle MF. Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol 2006;41(3):272-278.
28. Darrah TH, Prutsman-Pfeiffer JJ, Poreda RJ, Ellen Campbell M, Hauschka PV, Hannigan RE. Incorporation of excess gadolinium into human bone from medical contrast agents. Metallomics 2009;1(6):479-488.
29. Pietsch H, Raschke M, Ellinger-Ziegelbauer H, et al. The role of residual gadolinium in the induction of nephrogenic systemic fibrosis-like skin lesions in rats. Invest Radiol 2011;46(1):48-56.
30. Ogi S, Fukumitsu N, Tsuchida D, Uchiyama M, Mori Y, Matsui K. Imaging of bilateral striopallidodentate calcinosis. Clin Nucl Med 2002;27(10):721-724.
31. Telgmann L, Sperling M, Karst U. Determination of gadolinium-based MRI contrast agents in biological and environmental samples: a review. Anal Chim Acta 2013;764:1-16.
32. Kanda T, Osawa M, Oba H, et al. High signal intensity in dentate nucleus on unenhanced T1-weighted MR images: association with linear versus macrocyclic gadolinium chelate administration. Radiology doi: 10.1148/radiol.13131669. Published online January 27, 2015. Accessed February 5, 2015.
33. Tweedle MF, Kanal E, Muller R. Considerations in the selection of a new gadolinium-based contrast agent. Appl Radiol 2014.